Key facts
- VC Cell Therapy’s last known valuation is $43.9M (Nov 2023).
- It has raised $18.6M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Dai-Dan Company, RIMIX, Sysmex (Diagnostic Equipment), Yaskawa Electric.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for VC Cell Therapy
- ·The full record, as it builds
Funding rounds
No funding rounds for VC Cell Therapy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VC Cell Therapy
Developer of a biotechnology therapeutics designed to develop regenerative cell therapies for retinal degeneration diseases. The company produces retinal pigment epithelial cells and photoreceptor cells from allogeneic iPS cells, using automated manufacturing technology complemented with artificial intelligence analytics, enabling healthcare professionals to improve the treatments provided to patients.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2021
- Employees
- 50
- Website
- vcct.jp/
- Ownership
- Privately Held (backing)
VC Cell Therapy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VC Cell Therapy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VC Cell Therapy in its N-PORT filings yet. We sweep new filings monthly.